LIPT - Liraglutide in Polycystic Ovary Syndrome

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.

The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS.

70 women will be included in af RCT.

Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jens Faber
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• PCOS

• >18 years

• premenopausal

• BMI >25 og 25 and thereunder + insulin resistent

Exclusion Criteria (including):

• actualt or intended pregnancy

• inadeqvat contraception

• hormonal contraception within 6 weeks

• metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months

• medications affectiv hemostatic mechanisme

• diabetes or other severe comorbidity

• familar MEN

• ...